Contineum Therapeutics Inc (CTNM) USD0.001 A

Sell:$6.46Buy:$6.53$0.39 (5.59%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$6.46
Buy:$6.53
Change:$0.39 (5.59%)
Market closed | Prices delayed by at least 15 minutes
Sell:$6.46
Buy:$6.53
Change:$0.39 (5.59%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Key people

Carmine Stengone
Chairman of the Board, President, Chief Executive Officer
Peter T. Slover
Chief Financial Officer
Kristina Haeckl
Senior Vice President - Regulatory Affairs
Stephen L. Huhn
Chief Medical Officer, Senior Vice President - Clinical Development
Daniel S. Lorrain
Chief Science Officer
John Healy
General Counsel, Corporate Secretary
Stefan M. Larson
Director
Diego Miralles
Director
Clare R. Ozawa
Director
Sarah Boyce
Independent Director
Todd R. Brady
Independent Director
Click to see more

Key facts

  • EPIC
    CTNM
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US21217B1008
  • Market cap
    $180.58m
  • Employees
    41
  • Shares in issue
    19.14m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.